Clinical Trials Sponsored by EdiGene Inc.

Total 35633 results

EdiGene (GuangZhou) Inc.

Active, not recruiting

A Safety and Efficacy Study Evaluating ET-01 in Subjects With Transfusion Dependent β-Thalassaemia (ET-01)

Transfusion Dependent Beta-Thalassaemia

China
BeiGene USA, Inc.

Completed

A Study Assessing Pamiparib With Radiation and/or Temozolomide (TMZ) in Participants With Newly Diagnosed or Recurrent Glioblastoma

Brain and Central Nervous System Tumors

United States, Netherlands, Switzerland
EyeGene Inc.

Recruiting

Study to Safety, Tolerability and Immunogenicity of EG-COVII in Healthy Adult

COVID-19

Australia
Adagene Inc

Completed

Study of CD137 Agonist ADG106 With Advanced or Metastatic Solid Tumors and/or Non-Hodgkin Lymphoma

Solid Tumors, Non-Hodgkin Lymphoma

United States
Adagene Inc

Terminated

Study of ADG116 in Patients With Advanced/Metastatic Solid Tumors

Solid Tumor

United States
Adagene Inc

Recruiting

Study of ADG206 in Subjects With Advanced/Metastatic Solid Tumors

Advanced/Metastatic Solid Tumors

Australia
Adagene Inc

Recruiting

ADG126, ADG126 in Combination With Anti PD1 Antibody, and ADG126 in Combination With ADG106 in Advanced/Metastatic Solid Tumors

Advanced/Metastatic Solid Tumors

Singapore, Australia, United States
Adagene Inc

Active, not recruiting

A Phase 1b/2 Study of ADG116, ADG116 Combined With Anti-PD-1 Antibody or Anti-CD137 Antibody in Solid Tumors Patients

Advanced/Metastatic Solid Tumors

United States, Australia
Adagene (Suzhou) Limited

Completed

Study of ADG106 With Advanced or Metastatic Solid Tumors and/or Non-Hodgkin Lymphoma

Solid Tumor | Non-Hodgkin Lymphoma

China
enGene, Inc.

Recruiting

LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve

Superficial Bladder Cancer | Non-muscle Invasive Bladder Cancer With Carcinoma in Situ

United States
Adagene (Suzhou) Limited

Terminated

Study of ADG106 In Combination With PD-1 Antibody In Advanced or Metastatic Solid Tumors and/or Non Hodgkin Lymphoma

Solid Tumor | Non Hodgkin Lymphoma

China
EdiGene (GuangZhou) Inc.
PLA 923 Hospital

Active, not recruiting

A Study to Evaluate the Safety and Efficacy of ET-01 Transplantation in Subjects With Transfusion Dependent β-Thalassaemia.

Transfusion Dependent Beta-Thalassaemia

China
MediGene

Completed

Safety & Efficacy of NV1020 in Colorectal Cancer Metastatic to the Liver

Liver Neoplasms | Colorectal Cancer

United States
MediGene

Completed

Study Evaluating the Pharmacokinetic Profile of Novel Formulations of RHUDEX®

Formulation Finding

United Kingdom
MediGene

Completed

EndoTAG-1 in Triple Receptor Negative Breast Cancer Patients

Breast Neoplasms

Belgium, France, Poland, India, Romania, Ukraine
MediGene

Completed

A Trial Evaluating the Pharmacokinetics and Mode of Action of EndoTAG®-1 in Tumor Patients With Hepatic Metastases

Neoplasm Metastasis | Liver Cancer

Germany
MediGene

Completed

Systemic Exposure of Catechins From Veregen 15% Ointment in Patients With External Anogenital Warts and From Oral Intake of Green Tea Beverage in Healthy Volunteers

Anogenital Warts

Germany
MediGene

Terminated

Study Evaluating the Pharmacokinetic Profile of RhuDex® in a Tablet Formulation

Pharmacokinetics

United Kingdom
MediGene

Completed

EndoTAG-1 / Gemcitabine Combination Therapy to Treat Locally Advanced and/or Metastatic Adenocarcinoma of the Pancreas

Adenocarcinoma | Metastasis | Pancreas Neoplasms

Ukraine, Czech Republic, Hungary
MediGene

Completed

Phase-I Study Evaluating the Pharmacokinetic Profile of RhuDex®

Pharmacokinetics

United Kingdom
MediGene

Completed

Efficacy and Safety Study of Polyphenon E to Treat External Genital Warts

Condylomata Acuminata

United States, Argentina, Chile, Colombia, Mexico, Peru, Romania
MediGene

Completed

Safety and Effectiveness Study of G207, a Tumor-Killing Virus, in Patients With Recurrent Brain Cancer

Glioma | Glioblastoma | Astrocytoma
Leap Therapeutics, Inc.
BeiGene

Active, not recruiting

A Study of DKN-01 in Combination With Tislelizumab ± Chemotherapy in Patients With Gastric or Gastroesophageal Cancer (DisTinGuish)

Gastric Cancer | Gastric Adenocarcinoma | GastroEsophageal Cancer

United States, Korea, Republic of, Germany
BeiGene
Myriad Genetics, Inc.

Completed

Study to Assess Safety, Tolerability and Clinical Activity of BGB-290 in Combination With Temozolomide (TMZ) in Participants With Locally Advanced or Metastatic Solid Tumors

Locally Advanced or Metastatic Solid Tumors

Spain, Australia, United States, United Kingdom
Unigene Laboratories Inc.
GlaxoSmithKline

Completed

Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of PTH Analog Tablets in Postmenopausal Women

Postmenopausal Osteoporosis

Denmark, Estonia
Chinese PLA General Hospital
Peking University; EdiGene Inc.

Recruiting

TRAC and Power3 Genes Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B-NHL

Non Hodgkin's Lymphoma

China
BeiGene
SpringWorks Therapeutics, Inc.

Recruiting

Study of the Safety and Pharmacokinetics of BGB-283 (Lifirafenib) and PD-0325901 (Mirdametinib) in Participants With Advanced or Refractory Solid Tumors

Solid Tumor, Adult

Australia, United States
Medigene AG

Completed

DC Vaccination for Post-remission Therapy in AML

Acute Myeloid Leukemia

Norway
Medigene AG

Terminated

TCR Modified T Cells MDG1011 in High Risk Myeloid and Lymphoid Neoplasms

Feasibility | Tolerability | Safety | Treatment Efficacy

Germany
Medigene AG

Withdrawn

HA-1H TCR T Cell for Relapsed/Persistent Hematologic Malignancies After Allogeneic Stem Cell Transplantation

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Myeloproliferative Disorders | Multiple Myeloma | Myelofibrosis | Chronic Myeloid Leukemia | Acute Lymphoid Leukemia | Malignant Lymphoma

Netherlands
Immix Biopharma, Inc.
Novartis; BeiGene

Recruiting

Study of IMX-110 in Combination With Tislelizumab in Patients With Advanced Solid Tumors (IMMINENT-01)

Advanced Solid Tumor

Brazil
BeiGene
Myriad Genetic Laboratories, Inc.

Completed

The Safety, Pharmacokinetics and Antitumor Activity of BGB-A317 in Combination With BGB-290 in Participants With Advanced Solid Tumors

Solid Tumors

United States, Spain, United Kingdom, France, Australia, New Zealand
Laboratoire Boreaderme Inc.
Ecogene 21

Unknown

An Open Label Study to Evaluate the Safety and Efficacy of BOR15001L7 for the Treatment of Cold Sores in Patients With Recurrent Herpes Labialis

Recurrent Herpes Labialis
Adagene Inc
Merck Sharp & Dohme LLC

Recruiting

ADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors

Advanced/Metastatic Solid Tumors

Korea, Republic of, United States
National University Hospital, Singapore
Adagene Inc

Recruiting

A Phase Ib Safety lead-in, Followed by Phase II Trial of ADG106 in Combination With Neoadjuvant Chemotherapy in HER2 Negative Breast Cancer

Advanced Solid Tumor | HER2-negative Breast Cancer

Singapore
EyeGene Inc.
Novotech (Australia) Pty Limited

Active, not recruiting

Study to Assess the Safety, Tolerability and Explore the Immunogenicity of EG-COVID and EG-COVARo in Healthy Adult Volunteers

COVID-19 Vaccine

Australia
BeiGene

Not yet recruiting

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single- and Multiple-Ascending Doses and Food Effect of BGB-45035

Autoimmune Diseases | Healthy Volunteers | Healthy Subjects | Healthy Participants | Healthy Adult Participants
BeiGene

Recruiting

A Study of BGB-A445 in Combination With Other Investigational Agents in Participants With Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer

China, Korea, Republic of
BeiGene

Recruiting

A Study to Evaluate LBL-007 in Combination With Tislelizumab Plus Chemotherapy in Participants With Unresectable Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma

Esophageal Cancer | Esophageal Squamous Cell Carcinoma | Esophageal Squamous Cell Carcinoma by AJCC V8 Stage

China, Taiwan, Korea, Republic of, Thailand
BeiGene

Recruiting

Study to Evaluate the Efficacy and Safety of BGB-11417 in Participants With Waldenström's Macroglobulinemia

Waldenstrom Macroglobulinemia | Waldenstrom's Macroglobulinemia Recurrent | Waldenstrom's Macroglobulinemia Refractory

United States, Australia, China, Spain, United Kingdom
BeiGene

Recruiting

A Study of BGB-A3055, Alone and in Combination With Tislelizumab in Participants With Selected Advanced or Metastatic Solid Tumors

Solid Tumor | Advanced Solid Tumor | Metastatic Solid Tumor

United States, Australia
BeiGene

Recruiting

Tislelizumab in Combination With Investigational Agents in Participants With Head and Neck Squamous Cell Carcinoma

Head and Neck Cancer | Head and Neck Squamous Cell Carcinoma

China, Italy, Taiwan, Australia, Spain, Korea, Republic of, France, Thailand, United States, Georgia, Singapore, Canada
BeiGene

Recruiting

A Study to Evaluate the Safety and Efficacy of Zanubrutinib in Participants With Primary Membranous Nephropathy

Primary Membranous Nephropathy

China, United Kingdom, United States
BeiGene

Recruiting

Observational Study Evaluating the Efficacy and Safety of Zanubrutinib in Participants With Waldenström Macroglobulinemia

Waldenstrom Macroglobulinemia

United States, Puerto Rico
BeiGene

Recruiting

Efficacy, Safety, and Pharmacodynamics of Tislelizumab Monotherapy and Multiple Tislelizumab-based Immunotherapy Combinations in Participants With Resectable Non-Small Cell Lung Cancer

Non Small Cell Lung Cancer

China
BeiGene

Recruiting

Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Burton Tyrosine Kinase-Targeted Protein-Degrader

Follicular Lymphoma | Waldenström Macroglobulinemia | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Non-Hodgkin Lymphoma | B-cell Malignancy | Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | Richter's Transformation | DLBCL Unclassifiable

China
BeiGene

Recruiting

Treatment of CD79B Mutant Relapsed/Refractory Diffuse Large B-Cell Lymphoma With Bruton Tyrosine Kinase Inhibitor Zanubrutinib

Relapsed Diffuse Large B-cell Lymphoma | Refractory Diffuse Large B-cell Lymphoma

China
BeiGene

Recruiting

A Phase 1b/2 Study of BGB-11417in Monotherapy and in Various Combinations With Dexamethasone and Carfilzomib in Multiple Myeloma

Relapsed/Refractory Multiple Myeloma

United States, China, Australia, Korea, Republic of, United Kingdom, Canada, Brazil, New Zealand
BeiGene

Recruiting

A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer

NSCLC | Non-small Cell Lung Cancer

Japan, United States, France, Mexico, Germany, Argentina, Brazil, Korea, Republic of, Turkey
BeiGene

Recruiting

Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab

Follicular Lymphoma | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Chronic Lymphocytic Leukemia | Advanced Solid Tumor | Diffuse Large B Cell Lymphoma | Small Lymphocytic Lymphoma

Australia, China

3

Subscribe